Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 3/2013

01-09-2013 | Original Paper

The influence of genetic polymorphisms in MDR1 gene on breast cancer risk factors in Chinese

Authors: Yunhe Jia, Wenjing Tian, Shuai Sun, Peng Han, Weinan Xue, Mingqi Li, Yanlong Liu, Shixiong Jiang, Binbin Cui

Published in: Medical Oncology | Issue 3/2013

Login to get access

Abstract

Breast cancer (BC) is the most common cancer among women in the world. The human multidrug resistance 1 gene (MDR1) is potentially an important gene influencing the susceptibility to breast cancer. This study aimed to assess the association of MDR1 genetic polymorphisms with the susceptibility to BC. Overall, 353 BC patients and 360 cancer-free controls were enrolled. The clinical characteristics were summarized by questionnaires. The c.1564A > T genetic polymorphism was genotyped using created restriction site–polymerase chain reaction method. We found that no significant differences in the genotypic and allelic frequencies between BC patients and cancer-free controls. Furthermore, the distribution of BC patients’ risk factors was not significantly different among AA, AT, and TT genotypes. Our findings indicate that the c.1564A > T genetic polymorphism is not significantly associated with the susceptibility to BC in Chinese Han populations.
Literature
1.
Aapro MS. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001. Oncologist. 2001;6:376–85.PubMedCrossRef
2.
Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, Ebrahimi M. Breast cancer in Iran: an epidemiological review. Breast J. 2007;13:383–91.PubMedCrossRef
3.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.PubMedCrossRef
4.
Kusinska R, Gorniak P, Pastorczak A, Fendler W, Potemski P, Mlynarski W, Kordek R. Influence of genomic variation in FTO at 16q12.2, MC4R at 18q22 and NRXN3 at 14q31 genes on breast cancer risk. Mol Biol Rep. 2012;39:2915–9.PubMedCrossRef
5.
Chen G, Quan S, Hu Q, Wang L, Xia X, Wu J. Lack of association between MDR1 C3435T polymorphism and chemotherapy response in advanced breast cancer patients: evidence from current studies. Mol Biol Rep. 2012;39:5161–8.PubMedCrossRef
6.
Fan L, Zheng Y, Yu KD, Liu GY, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM. Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat. 2009;117:409–16.PubMedCrossRef
7.
Tatari F, Salek R, Mosaffa F, Khedri A, Behravan J. Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population. DNA Cell Biol. 2009;28:259–63.PubMedCrossRef
8.
9.
Larkin A, O’Driscoll L, Kennedy S, Purcell R, Moran E, Crown J, Parkinson M, Clynes M. Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int J Cancer. 2004;112:286–94.PubMedCrossRef
10.
Hoffmann J, Sommer A. Steroid hormone receptors as targets for the therapy of breast and prostate cancer–recent advances, mechanisms of resistance, and new approaches. J Steroid Biochem Mol Biol. 2005;93:191–200.PubMedCrossRef
11.
Turgut S, Yaren A, Kursunluoglu R, Turgut G. MDR1 C3435T polymorphism in patients with breast cancer. Arch Med Res. 2007;38:539–44.PubMedCrossRef
12.
Hussien YM, Gharib AF, Awad HA, Karam RA, Elsawy WH. Impact of DNA repair genes polymorphism (XPD and XRCC1) on the risk of breast cancer in Egyptian female patients. Mol Biol Rep. 2012;39:1895–901.PubMedCrossRef
13.
Fang Y, Zhao Q, Ma G, Han Y, Lou N. Investigation on MDR1 gene polymorphisms and its relationship with breast cancer risk factors in Chinese women. Med Oncol. 2013;30:375.PubMedCrossRef
14.
Cizmarikova M, Wagnerova M, Schonova L, Habalova V, Kohut A, Linkova A, Sarissky M, Mojzis J, Mirossay L, Mirossay A. MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J. 2010;10:62–9.PubMedCrossRef
15.
Gervasini G, Carrillo JA, Garcia M, San Jose C, Cabanillas A, Benitez J. Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. Cancer. 2006;107:2850–7.PubMedCrossRef
16.
17.
Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem. 2002;71:537–92.PubMedCrossRef
18.
Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M, Bodalski J, Robak T. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol. 2004;72:314–21.PubMedCrossRef
19.
George J, Dharanipragada K, Krishnamachari S, Chandrasekaran A, Sam SS, Sunder E. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. Clin Breast Cancer. 2009;9:161–5.PubMedCrossRef
20.
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA. 2000;97:3473–8.PubMedCrossRef
21.
Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315:525–8.PubMedCrossRef
22.
Sheng X, Zhang L, Tong N, Luo D, Wang M, Xu M, Zhang Z. MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies. Mol Biol Rep. 2012;39:7237–49.PubMedCrossRef
23.
Wang J, Wang B, Bi J, Li K, Di J. MDR1 gene C3435T polymorphism and cancer risk: a meta-analysis of 34 case-control studies. J Cancer Res Clin Oncol. 2012;138:979–89.PubMedCrossRef
24.
Ambrosone CB, Moysich KB, Furberg H, Freudenheim JL, Bowman ED, Ahmed S, Graham S, Vena JE, Shields PG. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res. 2003;5:R45–51.PubMedCrossRef
25.
Chang JH, Gertig DM, Chen X, Dite GS, Jenkins MA, Milne RL, Southey MC, McCredie MR, Giles GG, Chenevix-Trench G, Hopper JL, Spurdle AB. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study. Breast Cancer Res. 2005;7:R513–21.PubMedCrossRef
26.
Shin MH, Lee KM, Yang JH, Nam SJ, Kim JW, Yoo KY, Park SK, Noh DY, Ahn SH, Kim B, Kang D. Genetic polymorphism of CYP17 and breast cancer risk in Korean women. Exp Mol Med. 2005;37:11–7.PubMedCrossRef
27.
Daly AK, Steen VM, Fairbrother KS, Idle JR. CYP2D6 multiallelism. Method Enzymol. 1996;272:199–210.CrossRef
28.
Haliassos A, Chomel JC, Tesson L, Baudis M, Kruh J, Kaplan JC, Kitzis A. Modification of enzymatically amplified DNA for the detection of point mutations. Nucleic Acids Res. 1989;17:3606.PubMedCrossRef
29.
Yuan ZR, Li J, Li JY, Gao X, Xu SZ. SNPs identification and its correlation analysis with milk somatic cell score in bovine MBL1 gene. Mol Biol Rep. 2013;40:7–12.PubMedCrossRef
30.
Yuan ZR, Li JY, Li J, Zhang LP, Gao X, Gao HJ, Xu SZ. Investigation on BRCA1 SNPs and its effects on mastitis in Chinese commercial cattle. Gene. 2012;505:190–4.PubMedCrossRef
31.
Yuan ZR, Li JY, Li J, Gao X, Xu SZ. Effects of DGAT1 gene on meat and carcass fatness quality in Chinese commercial cattle. Mol Biol Rep. 2013;40:1947–54.PubMedCrossRef
32.
Zhao CJ, Li N, Deng XM. The establishment of method for identifying SNP genotype by CRS-PCR. Yi Chuan. 2003;25:327–9.PubMed
Metadata
Title
The influence of genetic polymorphisms in MDR1 gene on breast cancer risk factors in Chinese
Authors
Yunhe Jia
Wenjing Tian
Shuai Sun
Peng Han
Weinan Xue
Mingqi Li
Yanlong Liu
Shixiong Jiang
Binbin Cui
Publication date
01-09-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0601-0

Other articles of this Issue 3/2013

Medical Oncology 3/2013 Go to the issue

Original Paper

Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3

Original Paper

Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience

Original Paper

Effect of leuprolide acetate on ovarian function after cyclophosphamide–doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial

Letter to the Editor

The basic helix-loop-helix (bHLH) proteins in breast cancer progression

Original Paper

Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130/STAT3 pathway

Original Paper

Soluble ICAM-1 levels in small-cell lung cancer: prognostic value for survival and predictive significance for response during chemotherapy
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits